Cardiac experts emphasize the effectiveness of prasugrel in the treatment of acute Coronario syndrome, especially in diabetic patients

-Prof. Angiolillo, Dr. Worner Diz, Dr. Fernández Ortiz and Dr. López Sendón participate in the Simposio-Beca issues oral antiplatelet practices in the treatment of the SCA with new ”.

– Coincide in highlighting the new antiplatelet take over of the until now standard treatment (clopidogrel).

-Organized by the Alliance Daiichi Sankyo – Lilly in the framework of the Congress of the society Spanish of cardiology.

Maspalomas, 2011-October Experts agree: the new oral antiplatelet, as it is the case of prasugrel, are effective for the treatment of patients with acute Coronario syndrome (SCA) to a percutaneous coronary intervention (PCI), significantly reduce ischemic events the first year. proof of this is that the updating of Cardiology European and American guidelines for the management of patients with SCA without persistent ST segment elevation recommend the use of the new antiplatelet prasugrel and ticagrelor (combined with acetylsalicylic acid), relegating to a second plane clopidogrel, until now the standard therapy.

Thus it been highlighted four renowned cardiologists during the Symposium – scholarship questions oral antiplatelet practices in the treatment of the SCA with new ”, sponsored by the Alliance Daiichi Sankyo – Lilly, that has taken place within the framework of the Congress of the 2011 SEC, which was held from 20 to 22 October in Maspalomas (Gran Canaria).

Prof. Dominick Joseph Angiolillo, Director of the programme of research Cardiovascular of the College of Medicine of Jacksonville of the University of Florida and one of the leading world experts on antiagregación, has placed special emphasis on that prasugrel is positioned as a beneficial, practical and effective option for patients with diabetes with SCA are treated with PCIin the reduction of ischemic events, but without an increase in the rate of major bleeding ”.

for this reason, and based on his clinical practice, Prof. Angiolillo recommends the use of prasugrel as conventional treatment in people with diabetes to SCA under a PKI if they do not have contraindications, as for example, a stroke prior ”.

For his part, Dr. Fernando Worner Diz, Chief of the service of Cardiology of the Hospital Universitario Arnau de Vilanova de Lleida, has done a review of recent studies concluding that prasugrel has shown a very strong effect on the prevention of a dreaded complication as it is the stent thrombosis, as well as one much larger set of events in patients with diabetes reduction ”.

From his point of view, these two facts justify the administration of prasugrel in patients with acute coronary syndrome that is revascularizan being percutaneously, essential in diabetic patients. ”

the intervention of Dr. Antonio Fernández Ortiz, cardiologist intrusive and responsible for the coronary unit of the Clinical Hospital of Madrid, has gone on the same line to point to you could say that the new European guidelines do justice to equalize the degree and level of recommendation of 2 new inhibitors of receptor P2Y12 in this patient group. For both drugs will have to use caution in patients at risk of bleeding, but the vast majority of patients will be eligible to benefit from the more powerful, faster and more predictable antiplatelet effect these drugs have and therefore, the clinical impact will be very important ”.

Also, Dr. Fernández Ortiz has stressed the importance of facilitating the administration of drugs to achieve a greater adherence to treatment: patients with SCA takes on a daily basis a large number of pills, and many of them of life. That is why any initiative that serves to reduce the number of pills to take is important. In this scenario, the administration of any medication only once a day is seen as an advantage that facilitates the correct performance and adherence to treatment ”.

Finally, the Dr. José Luis López-Sendón, Chief of service of Cardiology of the Hospital Universitario La Paz (Madrid), who has moderated the Symposium pointed out that although these new treatments cost more at the same time, achieve greater effectiveness, which is an advantage in the short and long term, to reduce coronary occlusions in patients with SCA with or without ST segment elevation ”.

on the importance on the risk stratification of patients that indicate the new guides, López-Sendón reminded that in Spain, this process of stratification of the patient is either protocol for years, forcing measure risk on an ongoing basis (at each visit)(, in the not in the post-operative …). Here the update of the guides of Cardiology will not bring about any change ”.

About Daiichi Sankyo

The Daiichi Sankyo group is dedicated to the creation and supply of innovative pharmaceutical products that respond to the medical needs of patients both emerging and mature markets. While maintaining its portfolio of medicines for hypertension, Hyperlipidemia, and bacterial infections, the group works on the development of treatments for Thrombotic Disorders focusing on the discovery of new oncological and cardiovascular therapies.

About Lilly

Lilly, a company based on innovation, is developing one growing portfolio of pharmaceutical products through the application of research more Cap made both by its own laboratories around the world as well as through collaborations with prestigious scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers to some of the most urgent medical needs in the world through the supply of medicinal products and information.